Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Recentin (cediranib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

VEGFR inhibitor

Related drugs:

‹

›

No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	cediranib Sensitive: A2 - Guideline cediranib Sensitive : A2	cediranib Sensitive: A2 - Guideline cediranib Sensitive : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	cediranib Resistant: A2 - Guideline cediranib Resistant : A2	cediranib Resistant: A2 - Guideline cediranib Resistant : A2
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib + cediranib Sensitive: B - Late Trials olaparib + cediranib Sensitive : B	olaparib + cediranib Sensitive: B - Late Trials olaparib + cediranib Sensitive : B
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib + cediranib Sensitive: B - Late Trials olaparib + cediranib Sensitive : B	olaparib + cediranib Sensitive: B - Late Trials olaparib + cediranib Sensitive : B
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	olaparib + durvalumab + cediranib Sensitive: C3 – Early Trials olaparib + durvalumab + cediranib Sensitive : C3	olaparib + durvalumab + cediranib Sensitive: C3 – Early Trials olaparib + durvalumab + cediranib Sensitive : C3
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	olaparib + cediranib Sensitive: C3 – Early Trials olaparib + cediranib Sensitive : C3	olaparib + cediranib Sensitive: C3 – Early Trials olaparib + cediranib Sensitive : C3
BRAF V600E	Glioblastoma	BRAF V600E	Glioblastoma	cediranib Sensitive: C4 – Case Studies cediranib Sensitive : C4	cediranib Sensitive: C4 – Case Studies cediranib Sensitive : C4
MET amplification	Glioblastoma	MET amplification	Glioblastoma	cediranib Resistant: C4 – Case Studies cediranib Resistant : C4	cediranib Resistant: C4 – Case Studies cediranib Resistant : C4
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	olaparib + cediranib + 3-AP Sensitive: D – Preclinical olaparib + cediranib + 3-AP Sensitive : D	olaparib + cediranib + 3-AP Sensitive: D – Preclinical olaparib + cediranib + 3-AP Sensitive : D